Filtered By:
Therapy: Hormonal Therapy

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 218 results found since Jan 2013.

Hormone use and stroke
Publication date: Available online 14 March 2016 Source:Apollo Medicine Author(s): Pushpendra Nath Renjen, Dinesh M. Chaudhari, Mahir Meman Strokes are an important cause of disability and death among older women. Because many women use hormone therapy for the control of perimenopausal symptoms and to prevent osteoporosis after menopause, establishing whether such therapy has other health effects is of considerable clinical importance. Overall, 55% of strokes occur in women, and women account for nearly 60% of all stroke-related deaths. Women appear to be protected from heart disease and stroke before menopause. This ...
Source: Apollo Medicine - March 14, 2016 Category: Journals (General) Source Type: research

From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection.
This article is part of a Special Issue entitled SI:50th Anniversary Issue. PMID: 26740397 [PubMed - as supplied by publisher]
Source: Brain Research - December 29, 2015 Category: Neurology Authors: Engler-Chiurazzi EB, Singh M, Simpkins JW Tags: Brain Res Source Type: research

Cochrane corner: oral hormone therapy and cardiovascular outcomes in post-menopausal women
Introduction Hormone therapy (HT) is commonly prescribed for the relief of climacteric symptoms in post-menopausal women; 54% (620490) of women enrolled in the Million Women Study1 in the UK (mean age 56 years) have tried it and 31% (358252) use it. Observational studies have shown oral HT is associated with lower rates of cardiovascular disease in post-menopausal women2; however randomised controlled trials (RCTs) have presented mixed results. The 2002 publication of the Women's Health Initiative I (WHI I) reported an association between combined oestrogen and progestin use and increased rates of both coronary heart...
Source: Heart - December 11, 2015 Category: Cardiology Authors: Boardman, H., Hartley, L., Eisinga, A., Main, C., Figuls, M. R. I. Tags: Drugs: cardiovascular system, Cochrane Corner, Acute coronary syndromes, Venous thromboembolism, Epidemiology Editorials Source Type: research

Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks
Conclusions: The differences in RMST for the outcomes of the WHI study are too small to establish clinical risks related to hormone therapy use.
Source: Menopause - December 1, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy.
CONCLUSIONS: Increased cardiovascular death risks question the safety of annual HT discontinuation practice to evaluate whether a woman could manage without HT. PMID: 26414962 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - September 28, 2015 Category: Endocrinology Authors: Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O Tags: J Clin Endocrinol Metab Source Type: research

White matter hyperintensities, hot flushes and estrogen - are they related?
Abstract White matter hyperintensities (WMH) are areas of high intensity observed in brain MRI scans. They are usually seen in normal aging but also in a number of neurological and psychiatric disorders. One of the underlying mechanisms is ischemia, expressed as small vessel disease. Since the volume of WMH may correlate with cognition, and an ongoing debate links postmenopausal hormone therapy with stroke and a decline in certain cognitive domains, several MRI studies have addressed this potential association. Two major randomized, placebo-controlled trials - WHIMS and KEEPS, the first including elderly women and...
Source: Climacteric - September 2, 2015 Category: Geriatrics Authors: Pines A Tags: Climacteric Source Type: research

Dietary isoflavones, urinary isoflavonoids, and risk of ischemic stroke in women Nutritional epidemiology and public health
Conclusions: A habitually high intake of soy isoflavones may be associated with a modest but significant increase in risk of ischemic stroke in women. However, no association was shown for the urinary excretion of isoflavonoids.
Source: American Journal of Clinical Nutrition - September 1, 2015 Category: Nutrition Authors: Yu, D., Shu, X.-O., Li, H., Yang, G., Cai, Q., Xiang, Y.-B., Ji, B.-T., Franke, A. A., Gao, Y.-T., Zheng, W., Zhang, X. Tags: Nutritional epidemiology and public health Source Type: research

Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality
Conclusions: In absolute terms, the risk reductions mean 19 fewer CHD deaths and 7 fewer stroke deaths per 1,000 women using any HT for at least 10 years.
Source: Menopause - August 28, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”
Publication date: Available online 19 August 2015 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Frank Z. Stanczyk, Bhagu R. Bhavnani Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. This review examines critically the safety o...
Source: The Journal of Steroid Biochemistry and Molecular Biology - August 21, 2015 Category: Biochemistry Source Type: research

Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records
Conclusion: Our findings provide recent data on the types of menopausal symptoms experienced by mid-life women prescribed HT. Electronic medical records may be a rich source of data for future studies of menopausal symptoms in this population.
Source: BMC Women's Health - August 13, 2015 Category: OBGYN Authors: Matthew SussmanJeffrey TrocioCraig BestSebastian MirkinAndrew BushmakinRobert YoodMark FriedmanJoseph MenzinMichael Louie Source Type: research

Dietary isoflavones, urinary isoflavonoids, and risk of ischemic stroke in women.
CONCLUSIONS: A habitually high intake of soy isoflavones may be associated with a modest but significant increase in risk of ischemic stroke in women. However, no association was shown for the urinary excretion of isoflavonoids. PMID: 26245809 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - August 5, 2015 Category: Nutrition Authors: Yu D, Shu XO, Li H, Yang G, Cai Q, Xiang YB, Ji BT, Franke AA, Gao YT, Zheng W, Zhang X Tags: Am J Clin Nutr Source Type: research

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Hormone Therapy Increases Stroke and Venous Thromboembolism Risks in Postmenopausal Women.
According to this study. PMID: 26018007 [PubMed - as supplied by publisher]
Source: The American Journal of Nursing - May 29, 2015 Category: Nursing Authors: Carter D Tags: Am J Nurs Source Type: research

Hormone Therapy Increases Stroke and Venous Thromboembolism Risks in Postmenopausal Women
According to this study: * Hormone therapy in women who have reached menopause confers little protection against cardiovascular disease, but it significantly increases the risk of stroke and venous thromboembolic events. * A subgroup analysis showed some cardiovascular benefit when treatment was started less than 10 years after the onset of menopause.
Source: AJN - May 29, 2015 Category: Nursing Tags: Journal Watch Source Type: research

Long-term menopausal hormone therapy and health consequences - how to choose sides?
Abstract There is no debate any more on the good safety profile of postmenopausal hormone therapy (HT) in healthy perimenopausal and early postmenopausal women, but there are still many open issues related to the consequences of long-term HT, especially in older women. A recent Cochrane meta-analysis showed that women who started HT less than 10 years after the menopause had lower mortality and coronary heart disease (CHD), but more venous thromboembolism (DVT). However, in those who started treatment more than 10 years after the menopause, there was high-quality evidence that it had little effect on death or CHD ...
Source: Climacteric - May 11, 2015 Category: Geriatrics Authors: Pines A, Shapiro S Tags: Climacteric Source Type: research